Compare Hershey Co (HSY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs TransMedics Group Inc — how do they compare? Hershey Co trades at $171.69 (market cap $34.83B), while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: Hershey Co is far larger — about 13.6× TransMedics Group Inc's market cap, and Hershey Co pays a 3.38% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HSY | TMDX | |
|---|---|---|
Market Cap | $34.83B | $2.57B |
Sector | Consumer Staples | Technology |
52-Week High | $236.28 | $150.42 |
52-Week Low | $162.31 | $61.99 |
Enterprise Value | $39.63B | $2.97B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $170.63, down 0.46% on the day, with a bearish technical signal from moving averages. The company reported revenue of $11.69B for 2025 with a net income margin of 9.12%, though margins have compressed from prior years. Recent earnings have consistently beaten expectations, and the company announced a $1.45 dividend payable in June 2026. Analyst consensus is a 'Hold' with a price target of $207.82, indicating potential upside from current levels.
The outlook for HSY hinges on margin recovery as high cocoa costs cycle out. While valuation multiples appear elevated, consistent earnings beats and a solid dividend yield of approximately 3.4% provide support. Key risks include persistent volume weakness and competitive pressures. The stock presents a cautious opportunity for investors betting on a fundamental rebound in the second half of 2026.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
